OTCPicks.com’s Daily Small Cap and Microcap Newsletter presents a range of the hottest small cap stocks on trading on the OTC and OTCBB markets. In addition to our Newsletters, OTCPicks.com is quickly becoming the premier community destination for small cap and microcap traders to meet up and discuss their top stock picks. Visit http://www.otcpicks.com/microcap.htm today to join this growing community.
Our Stocks to Watch today include Applied DNA Sciences Inc. (OTCBB: APDN), MAP Pharmaceuticals Inc. (Nasdaq: MAPP), Origin Agritech Ltd. (Nasdaq: SEED), Cytokinetics Inc. (Nasdaq: CYTK) and Hemispherx Biopharma Inc. (Amex: HEB). For the complete newsletter please visit: http://www.otcpicks.com/daily-market-movers/index.php
For more in-depth coverage of small cap stocks visit http://www.otcpicks.com/microcap.htm
APPLIED DNA SCIENCES INCORPORATED (OTCBB: APDN) "Up 12.86% in morning trading" Company Profile: http://www.otcpicks.com/applied-dna-sciences.htm APDN sells patented DNA security solutions to protect products, brands and intellectual property from counterfeiting and diversion. SigNature DNA is a botanical mark used to authenticate products in a unique manner that essentially cannot be copied. APDN also provides BioMaterial GenoTyping(TM) by detecting genomic DNA in natural materials to authenticate finished products. Both technologies protect brands and products in a wide range of industries and provide a forensic chain of evidence that can be used to prosecute perpetrators.
MAP PHARMACEUTICALS INCORPORATED (NASDAQ: MAPP) "Up 163.81% in morning trading" Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops a diversified, well-funded pipeline of novel Toll-like Receptor (TLR) product candidates. Based on Dynavax’s proprietary technology platform, these products specifically modify the innate immune response to infectious, respiratory, autoimmune, and inflammatory diseases. Dynavax’s product programs are supported by global partnerships with leading pharmaceutical companies such as Merck & Co., Inc., GlaxoSmithKline, and AstraZeneca AB, as well as funding from Symphony Dynamo, Inc. and the National Institutes of Health.
ORIGIN AGRITECH LIMITED (NASDAQ: SEED) "Up 14.60% in morning trading" Founded in 1997 and headquartered in Beijing, Origin Agritech Limited is China’s leading, vertically-integrated agricultural technology company specializing in agri-biotech research, development and production to supply the growing populations of China. Origin develops, grows, processes, and markets crop seeds to farmers throughout China and parts of Southeast Asia via a network of approximately 3,800 first-level distributors and 65,000 second-level distributors and retailers. The hybrid seed industry is estimated at US $2.5 billion and that is expected to double within the next five years. The Company currently operates facilities in 30 of 32 provinces in China. Since Origin launched its first entirely internally developed seed in 2003, the Company has developed 26 proprietary corn seed products, 19 proprietary rice seed products, 5 proprietary cotton seed products and 4 proprietary canola seed products that are in commercial production and distribution as of December 2008.
CYTOKINETICS INCORPORATED (NASDAQ: CYTK) "Up 28.84% in morning trading" Cytokinetics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. The company's drug candidates and potential drug candidates have arisen from research activities that are directed towards the cytoskeleton. The cytoskeleton is a complex biological infrastructure that plays a fundamental role within every human cell. Cytokinetics' focus on the cytoskeleton enables it to develop novel and potentially safer and more effective classes of drug candidates directed at treatments for cardiovascular disease, cancer and other diseases.
HEMISPHERX BIOPHARMA INCORPORATED (AMEX: HEB) "Up 23.26% in morning trading" Hemispherx Biopharma, Inc. is a specialty pharma company engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx's flagship products include Alferon N Injection(r) (FDA approved for a category of sexually transmitted diseases) and the experimental therapeutics Ampligen(r) and Oragens(r). Ampligen(r) and Oragens(r) represent experimental RNA nucleic acids being developed for globally important debilitating diseases and disorders of the immune system. Hemispherx's platform technology includes large and small agent components for potential treatment of various severely debilitating and life threatening diseases. Hemispherx has in excess of 50 issued patents comprising its core intellectual property estate and a fully commercialized product (Alferon N Injection(r)). The Company wholly owns and exclusively operates a GMP certified manufacturing facility in the United States for commercial products.
About OTCPicks.com
OTCPicks.com is fast becoming the premier Internet destination for investors seeking information on smallcap and microcap companies. The web site features companies in Profile Campaigns, Executive Interviews and Research Reports authored by our financial writers. We publish our Daily Market Movers Digest Newsletter to opt-in investor members. OTCPicks.com presents the latest information for the discerning small cap and microcap investor. The site features informative articles on microcap investing, the top penny stock picks, and a wealth of small cap research on vertical markets. To feature a company on OTCPicks.com, please contact our publisher, Brian Dean at 972-546-3740, or via email at publisher@otcpicks.com.
Forward-Looking Statement:
This press release includes "forward-looking statements" within the meaning of the federal securities laws, commonly identified by such terms as "believes," "looking ahead," "anticipates," "estimates" and other terms with similar meaning. Although the Company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can give no assurance that these assumptions will prove to be correct. Important factors that could cause actual results to differ materially from the Company's projections and expectations are disclosed in the Company's filings with the Securities and Exchange Commission. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions. Disclosure: OTCPicks.com has been compensated two thousand five hundred dollars by a third party for APDN advertising and promotional services. Additionally OTCPicks.com has been compensated a total of five thousand dollars by BlueWave Advisors for multiple one week promotions of APDN. OTCPicks.com is not a registered investment advisers or broker/dealer. OTCPicks.com makes no recommendation that the purchase of securities of companies profiled in this website is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market their securities, investing in such securities is highly speculative and carries a high degree of risk.
